• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 24th March 2022

Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB.

Global TB deaths are increasing. CGD and OHE set out a “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for a breakthrough short, universal TB regimen tackling MDR strains. An earlier 1998 OHE publication argued for…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
TB_Adobe_sewcream-scaled-1

Global TB deaths are increasing. CGD and OHE set out a “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for a breakthrough short, universal TB regimen tackling MDR strains. An earlier 1998 OHE publication argued for the UK to move from universal use of BCG vaccination, unlikely to be cost-effective, targeting resources at high-risk groups. The UK discontinued routine TB vaccination in 2005. 

The theme of World TB Day 2022 is “Invest to End TB. Save Lives.” Much progress has been made in reducing deaths from TB, but, as a 2020 paper from OHE and Center for Global Development (CGD) authors highlighted (Chalkidou et al., 2020), the rate of decline is slow, and the 2035 Strategic Development Goal (SDG) and Convergence targets (with all middle and low income counties (MLICs) achieving the low mortality rates of the best performing ones) may not be achieved until 2074, nearly 40 years later than anticipated. Indeed, WHO has highlighted that decades of progress halted in 2020 with global TB deaths increasing.

The 2019 Lancet Commission on TB set out the need for more resources to increase the availability of treatment and for the strengthening of universal health coverage to support diagnosis and delivery. But it also highlighted the need for new treatments for multi-drug resistance (MDR) TB, and for better diagnostics and vaccines.  In 2020, CGD and OHE set out a blueprint for a novel financing mechanism to get a new universal regimen for TB, the “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for new TB drugs if and when innovators succeeded in developing and launching a breakthrough TB regimen, defined as a short, universal regimen which tackles different types of TB, including MDR strains. Five middle-income countries (MICs)—India, China, Indonesia, Russia, and South Africa—account for over 40 percent of TB cases and 55 percent of MDR cases. They will get the greatest benefit from new TB treatments. The MVAC would enable them to shape the innovation agenda, adding an HTA value-based purchase commitment (building on earlier advance market and purchase commitments) to “push” based development funded in product development partnerships.

Whilst the major burden is now in MLICs, TB has not gone away in the UK. But we should recognise the success achieved by the UK NHS.  OHE published more than 100 booklets on various diseases and conditions as part of a series on “current health problems”.   The first and the last of the disease state papers were on the same illness: tuberculosis, as set out in an earlier OHE blog.  

The 1962 publication noted that TB was the main cause of death in the UK at the end of the 19th century. Rates of decline accelerated after 1948 with the introduction of universal health coverage, new TB drugs, and, in 1953, a BCG childhood vaccine programme.  By 1960 TB incidence had been reduced to an estimated 20,000 cases and around 2,250 deaths which “opened up the possibility of the final defeat of TB in Britain within 15 years”.  The  1998 publication  noted that, however, that this optimism was misplaced. “The continual decline in TB-associated morbidity and mortality that had occurred throughout this century (except during the war-effected 1940s) has not been apparent during the current decade. The 1990s have been a period when TB notifications have levelled out and, indeed, have even increased. The global problem is even more acute.”  The WHO declared TB a global emergency in 1993. Nick Marchant, the OHE author, noted the rise of HIV infection as a risk factor for TB infection, the challenges delivering directly-observed treatment, short-course (DOTS) in some health care settings, and the rise of multi-drug resistant TB.

He argued for a shift in UK strategy, away from universal use of the BCG vaccination, which was unlikely to be cost-effective, towards a more targeted use of resources aimed at high-risk groups. The UK discontinued its routine routine programme to vaccinate schoolchildren against tuberculosis with BCG vaccine in 2005.  Despite this targeting, whilst the UK had an estimated 6000 cases in 1998, these increased to a peak in 2011 at 8250. However, they declined to 4000 cases in 2020 (UK Health Security Agency, 2021). The NHS is targeting further reductions to achieve the 2035 WHO target of a 90% reduction in incidence from 2015 levels in the 2021 TB Action Plan for England.  

Related Research

Office of Health Economics (1962). Progress against Tuberculosis. Available from Progress against Tuberculosis (ohe.org)

Marchant, N. (1998) Tuberculosis. OHE Series on Health. Available from https://www.ohe.org/publications/tuberculosis.

Kettler, H. and Towse, A. (2002) Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty. OHE Monograph. Available from https://www.ohe.org/publications/public-private-partnerships-research-and-development-medicines-and-vaccines-diseases

Towse, A. and Kettler, H. (2005) Advance price or purchase commitments to create markets for treatments for diseases of poverty: Lessons from three policies. Bulletin of the World Health Organization. 83(4), 301-307. Available from https://www.who.int/bulletin/volumes/83/4/en/301arabic.pdf

Mills, A. (2015) Universal Health Coverage: The Holy Grail?. OHE Monograph. Available from https://www.ohe.org/publications/universal-health-coverage-holy-grail.

Chalkidou, K., Garau, M., Silverman, R., and Towse A. (2020). Blueprint for a Market-Driven Value-Based Advance Commitment (MVAC) for Tuberculosis. Center for Global Development. Available at: https://www.cgdev.org/publication/blueprint-market-driven-value-based-advance-commitment-tuberculosis

Chalkidou, K., Towse, A., Silverman, R., Garau, M., Ramakrishnan, G., 2020. Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. BMJ Global Health. DOI: 10.1136/bmjgh-2019-002061 

  • Drug Development/R&D
  • Economics of Innovation
  • 60th Anniversary

Related Insights

Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!